Asset / Drug

Truqap

Drug and asset intelligence for Truqap with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

RegulatoryJune 16, 2026

Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 13, 2026

Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.

No catalysts indexed for this entity yet.

Topline Data

Monitor FDA's final approval decision and subsequent market launch strategies for Truqap.

June 16, 2026 · N/A

Topline Data

Monitor patient uptake, competitive responses, and any upcoming data from ongoing trials related to Truqap.

June 16, 2026 · N/A

Topline Data

Monitor the uptake of the VENTANA PTEN Assay in clinical settings and its impact on TRUQAP's market performance.

June 13, 2026 · N/A

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.